To assess the impact of PD-1 blockade on SFTSV replication, PBMCs derived from healthy individuals were treated with NbP45 or Tislelizumab, followed by infection with SFTSV (subtype E, JS-2013-14) at an MOI of 1. Here, PDCD1 is linked to infection.